Norovirus vaccine
Noroviruses are the most common cause of infectious acute gastroenteritis (AGE) in the United States and a major cause of gastroenteritis worldwide. The impact of AGE is seen in the high incidence of hospitalization and a growing socioeconomic cost to businesses dealing with epidemic outbreaks.
LigoCyte is developing a mucosal vaccine for the prevention of norovirus AGE under a contract from the Department of Defense. A mucosal vaccine combines the advantages of simple, painless administration and directs the immune response directly to the site of infection at the gastrointestinal epithelium.
Anthrax vaccine
Ongoing, grants and contracts from both the National Institutes of Health and the Department of Defense support the clinical development of LigoCyte’s unique mucosal vaccines including a vaccine against anthrax. LigoCyte scientists have demonstrated proof of concept of an intranasal vaccine comprised of multiple antigens. This proof of concept directly enhances other programs at LigoCyte through the analysis and development of technologies and delivery systems.
Influenza vaccine
LigoCyte is developing a vaccine for the prevention of annual and avian influenza infection in humans. LigoCyte’s influenza vaccine candidate is designed to address the shortcomings of current influenza vaccine technologies by utilizing cell-based manufacturing techniques, disposable manufacturing processes, and a technology platform that supports rapid antigen engineering and enhances heterosubtypic protection.
Anti-inflammatory antibodies
LigoCyte is developing therapeutic monoclonal antibodies to treat respiratory inflammation such as asthma and chronic obstructive pulmonary disease (COPD) and gastrointestinal inflammation including Crohn's disease and ulcerative colitis.
Other development programs